ArticleOncoimmunology2020

Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.

Soleine Medjebar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.